- Home
- PMCB vs APLM Comparison
PMCB vs APLM Comparison
Compare PMCB & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMCB
- APLM
- Stock Information
- Founded
- PMCB 1996
- APLM 2016
- Country
- PMCB United States
- APLM United States
- Employees
- PMCB N/A
- APLM N/A
- Industry
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- APLM Blank Checks
- Sector
- PMCB Health Care
- APLM Finance
- Exchange
- PMCB Nasdaq
- APLM Nasdaq
- Market Cap
- PMCB 13.9M
- APLM 15.6M
- IPO Year
- PMCB N/A
- APLM N/A
- Fundamental
- Price
- PMCB $1.62
- APLM $7.89
- Analyst Decision
- PMCB
- APLM Strong Buy
- Analyst Count
- PMCB 0
- APLM 2
- Target Price
- PMCB N/A
- APLM $425.00
- AVG Volume (30 Days)
- PMCB 13.7K
- APLM 106.0K
- Earning Date
- PMCB 12-24-2024
- APLM 08-14-2024
- Dividend Yield
- PMCB N/A
- APLM N/A
- EPS Growth
- PMCB N/A
- APLM N/A
- EPS
- PMCB 0.74
- APLM N/A
- Revenue
- PMCB N/A
- APLM $2,101,000.00
- Revenue This Year
- PMCB N/A
- APLM N/A
- Revenue Next Year
- PMCB N/A
- APLM N/A
- P/E Ratio
- PMCB $2.25
- APLM N/A
- Revenue Growth
- PMCB N/A
- APLM 70.54
- 52 Week Low
- PMCB $1.39
- APLM $6.50
- 52 Week High
- PMCB $2.58
- APLM $105.00
- Technical
- Relative Strength Index (RSI)
- PMCB 45.07
- APLM 42.42
- Support Level
- PMCB $1.61
- APLM $7.70
- Resistance Level
- PMCB $1.81
- APLM $8.88
- Average True Range (ATR)
- PMCB 0.11
- APLM 1.34
- MACD
- PMCB 0.00
- APLM -0.04
- Stochastic Oscillator
- PMCB 43.64
- APLM 24.77
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.